Publication | Open Access

Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas

MedicineImmunologyPreliminary ResultsTherapeutic EfficacyImmune Checkpoint InhibitorPharmacotherapyInterferon GenesImmunotherapyAdvanced Solid TumorsRadiation OncologyNovel Therapy